Developers Restart Methotrexate Production Following Shortage

News
Article

Continued manufacturing of methotrexate may improve access to chemotherapy for patients with breast cancer, lung cancer, and other malignancies in the United States.

According to findings reported by American Society of Health-System Pharmacists (ASHP), methotrexate injections at 25 mg/mL, 2 mL, 10 mL, and 40 mL preservative-free vials were on back order at Accord following manufacturing delays.

According to findings reported by American Society of Health-System Pharmacists (ASHP), methotrexate injections at 25 mg/mL, 2 mL, 10 mL, and 40 mL preservative-free vials were on back order at Accord following manufacturing delays.

Developer Accord Healthcare has renewed production of the frequently used agent methotrexate during an ongoing shortage of oncology agents in the United States, according to a press release from Reuters.1

Resumed production of the injectable chemotherapy agent may increase access to treatment for patients with pediatric acute lymphoblastic leukemia, breast cancer, lung cancer, and specific subtypes of head and neck cancers. The FDA previously announced its goal to identify new manufacturers to mitigate the methotrexate shortage in June 2023.

According to findings reported by American Society of Health-System Pharmacists (ASHP), methotrexate injections at 25 mg/mL, 2 mL, 10 mL, and 40 mL preservative-free vials were on back order at Accord following manufacturing delays.2 Additionally, other manufacturers including Fresenius Kabi, Pfizer, Teva, and Hikma had methotrexate injections on back order due to increased demand amid the ongoing chemotherapy shortages in the United States.

In terms of navigating the limited supply of methotrexate in the country, the ASHP recommended administering alternative, patient-specific agents based on renal function, liver function, and type and location of the neoplasm, although the organization cautioned that methotrexate could not be substituted for any one single agent. Institutions were also advised to monitor methotrexate supplies prior to initiating chemotherapeutic regimens, and switching to alternative combinations in the case of inadequate resources.

The organization also advised for practices to save preservative-free methotrexate for intrathecal administration and to consult Hematology/Oncology specialists to receive patient- and neoplasm-specific treatment recommendations. Another recommendation included employing treatment with oral methotrexate for indications outside of oncology.

Current shortages of chemotherapeutic agents including methotrexate, carboplatin, and cisplatin are believed to be linked to an FDA inspection of a manufacturing plant.3 After failing to reach the quality standards established by the regulatory agency, the facility halted production of the aforementioned drugs; resolving these concerns has become an ongoing priority.

According to findings from a survey conducted by the National Comprehensive Cancer Network (NCCN) Best Practices Committee across 27 NCCN Member Institutions within the United States in May 2023, 93% of practices reported a shortage of carboplatin.3,4 Results from the survey also spotlighted a lack of adequate cisplatin supplies, according to 70% of the surveyed institutions.

Additional findings from the survey highlighted that 100% of practices were able to keep patients on cisplatin with no delays or claim denials. Moreover, 64% of surveyed practices were able to continue administering carboplatin to patients who were already receiving the agent.

The FDA sought to mitigate the chemotherapy drug shortages by importing these agents from alternative sources. For instance, the regulatory agency arranged an agreement with Chinese manufacturers to temporarily import cisplatin in May 2023.5 Moreover, the agency made an effort to relabel these products and add English labels to packaging as means of ensuring safety for buyers.3

References

  1. Accord resumes production of cancer drug methotrexate amid supply shortage. News release. Reuters. November 7, 2023. Accessed November 8, 2023. https://yhoo.it/3QRh3EY
  2. Methotrexate injection. American Society of Health-System Pharmacists. November 8, 2023. Accessed November 8, 2023. https://bit.ly/3u5XKix
  3. Cancer drug shortage 2023: commitment to our community. News release. University of Utah Huntsman Cancer Institute. July 5, 2023. Accessed November 8, 2023. https://bit.ly/3QPSfNM
  4. NCCN releases statement addressing ongoing chemotherapy shortages; shares survey results finding more than 90% of cancer centers are impacted. News release. National Comprehensive Cancer Network. June 7, 2023. Accessed November 8, 2023. https://prn.to/40szN0M
  5. Temporary importation of CISplatin injection with non-U.S. labeling to address drug shortage. FDA. May 24, 2023. Accessed November 8, 2023. https://shorturl.at/eiPQZ
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Updated ASCO Guideline Issues Vaccine Recommendations in Cancer Populations

March 31st 2024
Article

An updated guideline from ASCO highlights appropriate use of vaccines for patients with cancer receiving treatments such as CAR T-cell therapy or B-cell depleting therapy.

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.

FDA Clears IND for Novel Molecular Glue in Advanced Solid Tumors

March 29th 2024
Article

Investigators will evaluate the preliminary efficacy and safety of NST-628 in adult patients with solid tumors harboring mutations in the RAS-MAPK pathway as part of a phase 1 trial.